Bioequivalence study of Tofaxha 5mg
Not Applicable
Completed
- Conditions
- In this study, the disease is not examined. The subject of the study is the bioequivalence study of Tofacitinib 5mg tablet of test and reference in healthy volunteers..
- Registration Number
- IRCT20200623047902N2
- Lead Sponsor
- Zistdaru Danesh Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (Liver, Heart and Kidney)
Body Mass Index (18-28)
Conscious Consciousness
Age (18-60)
Exclusion Criteria
Smoking
History of cardiovascular disease
History of liver and kidney disease
Pregnancy
Alcoholism and Narcoticism
History of allergy to Tofacitinib
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Tofacitinib's JAK-STAT pathway inhibition in rheumatoid arthritis?
How does Tofaxha 5mg compare to Xeljanz 5mg in bioequivalence and JAK1/3 inhibition efficacy for RA?
Which biomarkers correlate with Tofacitinib response in JAK inhibitor-treated rheumatoid arthritis patients?
What are the safety profiles of Tofacitinib 5mg in healthy volunteers versus rheumatoid arthritis populations?
How do Tofacitinib's pharmacokinetics compare to other JAK inhibitors like Baricitinib in IRCT20200623047902N2?